MAPT and frontotemporal dementia: Transgenic mice expressing mutant tau variants (e.g., P301S and P301L) develop progressive frontotemporal neurodegeneration, synaptic loss, gliosis, and behavioral abnormalities resembling behavioral variant FTD, making them valuable platforms for studying tau-mediated neurotoxicity and for testing anti-tau therapeutic strategies.